AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25054399 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic alone (1.5 mL of 1% preservative-free lidocaine)
Number of subjects: 120
Study 25054399 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic with steroid (1% lidocaine and 3 mg betamethasone)
Number of subjects: 120
Study 25054399 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic alone
Number of subjects: 120
Study 25054399 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic with steroid
Number of subjects: 120
Study 23747768 — intervention group
Group type: EXPERIMENTAL
Intervention: qili qiangxin capsules
Number of subjects: 512
Study 23747768 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 512
Study 20354688 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 50 mg
Number of subjects: 12
Study 20354688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18191056 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0
Study 18191056 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 16933160 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewires with surface markers (marker group)
Number of subjects: 60
Study 16933160 — intervention group
Group type: COMPARATOR
Intervention: Conventional guidewires (control group)
Number of subjects: 60
Study 14568737 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine plus zidovudine
Number of subjects: 1119
Study 14568737 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine alone
Number of subjects: 1119
Study 10986188 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Number of subjects: 0
Study 10986188 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0
Study 10986188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 0
Study 10986188 — intervention group
Group type: COMPARATOR
Intervention: Phenothiazines, lignocaine (lidocaine), ketorolac, ergot alkaloids, metoclopramide hydrochloride, triptans, haloperidol, pethidine (meperidine hydrochloride), magnesium sulfate
Number of subjects: 0
Study 8757203 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 micrograms, once daily)
Number of subjects: 50
Study 8757203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1343475 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative laparoscopy in ART procedures (GIFT, ZIFT, TET)
Number of subjects: 0
Study 3905326 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide
Number of subjects: 30
Study 3905326 — intervention group
Group type: COMPARATOR
Intervention: HCT-triamterene
Number of subjects: 30
Study 29966428 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustered campaign extended care program (12 sessions delivered in three, 4‐week clusters)
Number of subjects: 269
Study 29966428 — intervention group
Group type: COMPARATOR
Intervention: Self-directed control
Number of subjects: 269
Study 30868305 — intervention group
Group type: EXPERIMENTAL
Intervention: Spreader flaps used in combination with spreader grafts (Group 1)
Number of subjects: 264
Study 30868305 — intervention group
Group type: COMPARATOR
Intervention: Spreader flaps used alone (Group 2)
Number of subjects: 264
Study 30868305 — intervention group
Group type: EXPERIMENTAL
Intervention: Spreader grafts used alone (Group 3)
Number of subjects: 264
Study 30868305 — intervention group
Group type: COMPARATOR
Intervention: Neither spreader flaps nor grafts used (Group 4)
Number of subjects: 264
Study 30511947 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric PT at posttest (80.0% of pretest)
Number of subjects: 36
Study 30511947 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric PT at 5-min recovery (87.8% of pretest)
Number of subjects: 36
Study 30511947 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle blood flow at posttest
Number of subjects: 36
Study 30511947 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle blood flow recovery
Number of subjects: 36
Study 30511947 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular responses
Number of subjects: 36
Study 26748844 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 139
Study 26748844 — intervention group
Group type: COMPARATOR
Intervention: Alpha-blockers
Number of subjects: 139
Study 26748844 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 139
Study 26748844 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin converting enzyme inhibitors (ACEi)
Number of subjects: 139
Study 24998674 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasonography group (n=160)
Number of subjects: 320
Study 24998674 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=160)
Number of subjects: 320
Study 22342789 — intervention group
Group type: EXPERIMENTAL
Intervention: Early appendectomy
Number of subjects: 131
Study 22342789 — intervention group
Group type: COMPARATOR
Intervention: Interval appendectomy
Number of subjects: 131
Study 20485492 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg/day for 5 days)
Number of subjects: 900
Study 20485492 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 900
Study 17365774 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch plus tailored brief motivational intervention, quit date behavioral skills counseling, and relapse prevention follow-up session
Number of subjects: 383
Study 17365774 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch plus brief advice using the National Cancer Institute's 4A's model
Number of subjects: 383
Study 12938828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin ointment applied twice per day for 7 days
Number of subjects: 47
Study 12938828 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (no intervention)
Number of subjects: 47
Study 10720024 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel applied at four sites (left and right arms/shoulders and left and right abdomen)
Number of subjects: 9
Study 10720024 — intervention group
Group type: COMPARATOR
Intervention: Transdermal testosterone gel applied at one site (left arm/shoulder)
Number of subjects: 9
Study 10720024 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel applied at four sites
Number of subjects: 9
Study 10720024 — intervention group
Group type: COMPARATOR
Intervention: Transdermal testosterone gel applied at one site
Number of subjects: 9
Study 8740312 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEpo) 300 IU/Kg per week for 4 weeks
Number of subjects: 14
Study 8740312 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 14
Study 1389644 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide injection
Number of subjects: 60
Study 1389644 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine
Number of subjects: 60
Study 3937968 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin treatment
Number of subjects: 90
Study 3937968 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Mitomycin treatment)
Number of subjects: 90
Study 31406230 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine MFGM supplemented experimental formula (EF)
Number of subjects: 0
Study 31406230 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 0
Study 31406230 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed infants
Number of subjects: 0
Study 28202441 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydrated (EU)
Number of subjects: 12
Study 28202441 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydrated (HY)
Number of subjects: 12
Study 28202441 — intervention group
Group type: COMPARATOR
Intervention: Hypohydration (HY)
Number of subjects: 12
Study 25875940 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 8
Study 25875940 — intervention group
Group type: COMPARATOR
Intervention: Oral levodopa-carbidopa (LC-oral)
Number of subjects: 8
Study 23648698 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenalectomy
Number of subjects: 180
Study 23648698 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 180
Study 23648698 — intervention group
Group type: COMPARATOR
Intervention: Primary hypertensive patients (control group)
Number of subjects: 180
Study 23648698 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenalectomy and Medical therapy (PA patients)
Number of subjects: 180
Study 21311869 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted implantation
Number of subjects: 30
Study 21311869 — intervention group
Group type: COMPARATOR
Intervention: Conventional implantation
Number of subjects: 30
Study 19106196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of BMPC
Number of subjects: 67
Study 19106196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 17404349 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10 microg subcutaneous abdominal injections twice daily for 16 weeks)
Number of subjects: 233
Study 17404349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous abdominal injections twice daily for 16 weeks)
Number of subjects: 233
Study 17404349 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 233
Study 17404349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 15082281 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative resting ischaemia
Number of subjects: 33
Study 15082281 — intervention group
Group type: COMPARATOR
Intervention: Surgical ischaemic preconditioning protocol
Number of subjects: 33
Study 15082281 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer ischaemic time
Number of subjects: 33
Study 15082281 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing values of cycle efficiency
Number of subjects: 33
Study 10981212 — intervention group
Group type: EXPERIMENTAL
Intervention: WHOQOL-BREF
Number of subjects: 71
Study 10981212 — intervention group
Group type: EXPERIMENTAL
Intervention: WHOQOL-100
Number of subjects: 71
Study 10981212 — intervention group
Group type: COMPARATOR
Intervention: Non-transplanted liver disease controls
Number of subjects: 71
Study 8822986 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (1 mg)
Number of subjects: 20
Study 8822986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1444500 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% topical minoxidil applied three times daily
Number of subjects: 32
Study 1444500 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 32
Study 1444500 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (6-week taper)
Number of subjects: 32
Study 1444500 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% topical minoxidil (open trial)
Number of subjects: 32
Study 6361300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (24 g/day)
Number of subjects: 1000
Study 6361300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 29624459 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 50
Study 29624459 — intervention group
Group type: COMPARATOR
Intervention: Control (antioxidant therapy)
Number of subjects: 50
Study 29649666 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Smoker (AS) group
Number of subjects: 320
Study 29649666 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Smoker (PS) group
Number of subjects: 320
Study 29649666 — intervention group
Group type: COMPARATOR
Intervention: Never Smoker (NS) group
Number of subjects: 320
Study 27688166 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate-coated implants
Number of subjects: 16
Study 27688166 — intervention group
Group type: COMPARATOR
Intervention: Control (uncoated) implants
Number of subjects: 16
Study 27688166 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both implant types
Number of subjects: 16
Study 24904022 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain and legume group
Number of subjects: 99
Study 24904022 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet with refined rice)
Number of subjects: 99
Study 22442825 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 10 mg
Number of subjects: 13
Study 22442825 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 25 mg
Number of subjects: 13
Study 22442825 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg
Number of subjects: 13
Study 22442825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 19736246 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day MCI-196
Number of subjects: 120
Study 19736246 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/day MCI-196
Number of subjects: 120
Study 19736246 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g/day MCI-196
Number of subjects: 120
Study 19736246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 19736246 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of MCI-196
Number of subjects: 120
Study 18932258 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-510 20 mg QD
Number of subjects: 49
Study 18932258 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-510 50 mg QD
Number of subjects: 49
Study 18932258 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-510 100 mg QD
Number of subjects: 49
Study 18932258 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-510 10 mg twice daily
Number of subjects: 49
Study 18932258 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-510 25 mg twice daily
Number of subjects: 49
Study 18932258 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-510 50 mg twice daily
Number of subjects: 49
Study 18932258 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 16187776 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 96
Study 16187776 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment alone
Number of subjects: 96
Study 16187776 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy after 6 months of drug treatment alone
Number of subjects: 96
Study 14507272 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of oral calcium carbonate
Number of subjects: 23
Study 14507272 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of oral calcium carbonate
Number of subjects: 23
Study 14507272 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of open-label calcium carbonate
Number of subjects: 23
Study 14507272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10760541 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease nurse specialist (PDNS) care
Number of subjects: 108
Study 10760541 — intervention group
Group type: COMPARATOR
Intervention: Consultant Neurologist care (control)
Number of subjects: 108
Study 8777827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet with 6.9 g of urea added (LP-U1)
Number of subjects: 6
Study 8777827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet with 13.7 g of urea added (LP-U2)
Number of subjects: 6
Study 8777827 — intervention group
Group type: COMPARATOR
Intervention: Reference diet (REF)
Number of subjects: 6
Study 8777827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LP)
Number of subjects: 6
Study 8777827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diets (LP, LP-U1, LP-U2)
Number of subjects: 6
Study 1519831 — intervention group
Group type: EXPERIMENTAL
Intervention: LTC4
Number of subjects: 8
Study 1519831 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 8
Study 1519831 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 8
Study 31999530 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE-pulse measured during laboratory activities (sitting, walking, running, cycling)
Number of subjects: 37
Study 31999530 — intervention group
Group type: EXPERIMENTAL
Intervention: Averaging outcome of each activity-type specific equation based on TEE-pulse from laboratory data
Number of subjects: 37
Study 31999530 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction method applied to free-living data
Number of subjects: 37
Study 31999530 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity classification and use of activity-selective prediction equations
Number of subjects: 37
Study 30639788 — intervention group
Group type: EXPERIMENTAL
Intervention: Bokutoh Positive group
Number of subjects: 5442
Study 30639788 — intervention group
Group type: COMPARATOR
Intervention: Bokutoh Negative group
Number of subjects: 5442
Study 26872548 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose casein (HP)
Number of subjects: 13
Study 26872548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose casein (LP)
Number of subjects: 13
Study 26872548 — intervention group
Group type: COMPARATOR
Intervention: Control (C) saline
Number of subjects: 13
Study 25894705 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive suicide assessment group
Number of subjects: 282
Study 25894705 — intervention group
Group type: COMPARATOR
Intervention: Control assessment group
Number of subjects: 282
Study 24020602 — intervention group
Group type: EXPERIMENTAL
Intervention: Community care workers (CCWs) trained and supervised to provide TB-HIV/PMTCT services
Number of subjects: 0
Study 24020602 — intervention group
Group type: COMPARATOR
Intervention: Control CCWs
Number of subjects: 0
Study 24020602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention CCWs
Number of subjects: 0
Study 21334697 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation and NMES
Number of subjects: 20
Study 21334697 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 20
Study 21030711 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg)
Number of subjects: 1484
Study 21030711 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose tinzaparin (100 IU/kg)
Number of subjects: 1484
Study 21030711 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tinzaparin (175 IU/kg)
Number of subjects: 1484
Study 21030711 — intervention group
Group type: EXPERIMENTAL
Intervention: Total anterior circulation syndrome
Number of subjects: 1484
Study 21030711 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial anterior circulation syndrome
Number of subjects: 1484
Study 21030711 — intervention group
Group type: EXPERIMENTAL
Intervention: Large vessel stroke
Number of subjects: 1484
Study 21030711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioembolic stroke
Number of subjects: 1484
Study 21030711 — intervention group
Group type: EXPERIMENTAL
Intervention: AHTI presence
Number of subjects: 1484
Study 17545846 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate stenting of the SVC followed by mediastinal RT within a week
Number of subjects: 19
Study 17545846 — intervention group
Group type: COMPARATOR
Intervention: Palliative RT to the mediastinum
Number of subjects: 19
Study 15792258 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP training
Number of subjects: 19
Study 12213142 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy (low-risk/low-benefit)
Number of subjects: 685
Study 12213142 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy surgery (high-risk/high-benefit)
Number of subjects: 685
Study 12213142 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracranial-to-intracranial bypass surgery (high-risk/unknown benefit)
Number of subjects: 685
Study 9799345 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 56
Study 9799345 — intervention group
Group type: EXPERIMENTAL
Intervention: PET
Number of subjects: 56
Study 9799345 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual correlation (PET+CT)
Number of subjects: 56
Study 9799345 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion (PET+CT)
Number of subjects: 56
Study 7609571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium loading (1 ml/kg of 10% NaCl infused for 15 minutes)
Number of subjects: 44
Study 2784648 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-dapsone
Number of subjects: 78
Study 2784648 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 78
Study 68383 — intervention group
Group type: EXPERIMENTAL
Intervention: WRL 105 strain live influenza vaccine
Number of subjects: 44
Study 68383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 31386106 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 egg per day
Number of subjects: 660
Study 31386106 — intervention group
Group type: COMPARATOR
Intervention: Control (no eggs provided)
Number of subjects: 660
Study 29083331 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mcg/kg of remifentanil
Number of subjects: 59
Study 29083331 — intervention group
Group type: COMPARATOR
Intervention: 2 ml normal saline (control)
Number of subjects: 59
Study 29083331 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil
Number of subjects: 59
Study 29083331 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 59
Study 25357090 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected priming (379 ± 44 W)
Number of subjects: 10
Study 25357090 — intervention group
Group type: COMPARATOR
Intervention: Intermittent priming at 100% of Wpeak (376 ± 45 W)
Number of subjects: 10
Study 25357090 — intervention group
Group type: COMPARATOR
Intervention: Intermittent priming at 150% of Wpeak (374 ± 48 W)
Number of subjects: 10
Study 25357090 — intervention group
Group type: COMPARATOR
Intervention: All-out priming (357 ± 45 W)
Number of subjects: 10
Study 22659021 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS1200
Number of subjects: 12
Study 22659021 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study 21593114 — intervention group
Group type: EXPERIMENTAL
Intervention: ronacaleret (100, 200, 300, or 400 mg oral once daily)
Number of subjects: 569